Search

Your search keyword '"Krug HF"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Krug HF" Remove constraint Author: "Krug HF"
73 results on '"Krug HF"'

Search Results

1. Diverse Applications of Nanomedicine

2. The DaNa projects: public communication of (nano)material safety data-from conspiracy theories to study quality.

3. Editorial: Methods and protocols in nanotoxicology.

4. A weight of evidence review of the genotoxicity of titanium dioxide (TiO 2 ).

5. A Systematic Review on the Hazard Assessment of Amorphous Silica Based on the Literature From 2013 to 2018.

6. Collection of Controlled Nanosafety Data-The CoCoN-Database, a Tool to Assess Nanomaterial Hazard.

7. Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.

8. A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment.

9. Cause-and-Effect Analysis as a Tool To Improve the Reproducibility of Nanobioassays: Four Case Studies.

10. The uncertainty with nanosafety: Validity and reliability of published data.

12. The DaNa 2.0 Knowledge Base Nanomaterials-An Important Measure Accompanying Nanomaterials Development.

13. Uptake of label-free graphene oxide by Caco-2 cells is dependent on the cell differentiation status.

14. Environmental benefits and concerns on safety: communicating latest results on nanotechnology safety research-the project DaNa 2.0 .

15. Diverse Applications of Nanomedicine.

16. Green Toxicology: a strategy for sustainable chemical and material development.

17. Toward achieving harmonization in a nano-cytotoxicity assay measurement through an interlaboratory comparison study.

18. From in vivo to in vitro: The medical device testing paradigm shift.

19. Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex Vivo Human Placental Perfusion Model.

20. Transfer studies of polystyrene nanoparticles in the ex vivo human placenta perfusion model: key sources of artifacts.

21. Use of Cause-and-Effect Analysis to Design a High-Quality Nanocytotoxicology Assay.

22. Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology.

23. Nanosafety research--are we on the right track?

24. Classification framework for graphene-based materials.

25. Addition of nanoscaled bioinspired surface features: A revolution for bone related implants and scaffolds?

26. Comparability of in vitro tests for bioactive nanoparticles: a common assay to detect reactive oxygen species as an example.

27. Gene expression profiling of immune-competent human cells exposed to engineered zinc oxide or titanium dioxide nanoparticles.

28. Determination of the transport rate of xenobiotics and nanomaterials across the placenta using the ex vivo human placental perfusion model.

29. In vitro mechanistic study towards a better understanding of ZnO nanoparticle toxicity.

30. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.

31. Effects of subtoxic concentrations of TiO2 and ZnO nanoparticles on human lymphocytes, dendritic cells and exosome production.

32. Pulmonary surfactant coating of multi-walled carbon nanotubes (MWCNTs) influences their oxidative and pro-inflammatory potential in vitro.

33. Caspase-10 is the key initiator caspase involved in tributyltin-mediated apoptosis in human immune cells.

34. Evidence maps: communicating risk assessments in societal controversies: the case of engineered nanoparticles.

35. Nanomaterial cell interactions: are current in vitro tests reliable?

36. 120 years of nanosilver history: implications for policy makers.

37. Nanotoxicology: an interdisciplinary challenge.

38. A comparison of acute and long-term effects of industrial multiwalled carbon nanotubes on human lung and immune cells in vitro.

39. The adsorption of biomolecules to multi-walled carbon nanotubes is influenced by both pulmonary surfactant lipids and surface chemistry.

40. Barrier capacity of human placenta for nanosized materials.

41. Effects of carbon nanotubes on primary neurons and glial cells.

42. C60 fullerene: a powerful antioxidant or a damaging agent? The importance of an in-depth material characterization prior to toxicity assays.

43. Nanomaterial cell interactions: how do carbon nanotubes affect cell physiology?

44. The response of a co-culture lung model to fine and ultrafine particles of incinerator fly ash at the air-liquid interface.

45. Peptoidic amino- and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus.

46. Cytotoxicity of TBBPA and effects on proliferation, cell cycle and MAPK pathways in mammalian cells.

47. Influence of platinum, palladium and rhodium as compared with cadmium, nickel and chromium on cell viability and oxidative stress in human bronchial epithelial cells.

48. Solid-phase synthesis, bioconjugation, and toxicology of novel cationic oligopeptoids for cellular drug delivery.

49. Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants.

50. Nanoparticulate vanadium oxide potentiated vanadium toxicity in human lung cells.

Catalog

Books, media, physical & digital resources